Expert Review of Pharmacoeconomics & Outcomes Research

Papers
(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
How to create value with constrained budgets in oncological care? A narrative review55
The value of cycleways to improve population physical activity levels: a systematic review of economic evaluations47
Social care data in the UK; current landscape, challenges, and future recommendations41
Engagement of medication users in the development and implementation of digital medication adherence technologies: a multi-stakeholder study39
Economic value of knowing BRCA status: BRCA testing for prostate cancer prevention and optimal treatment36
Indication-based pricing of the pharmaceuticals in Croatia: case-study25
Adherence to augmentation therapy for the treatment of major depressive disorder23
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology19
Clinical and economic impact analysis of viscosupplementation with hylan G-F 20 versus hyaluronic acids and no viscosupplementation for the treatment of knee osteoarthritis in Colombia16
Cost per responder analysis of lebrikizumab versus tralokinumab in moderate to severe atopic dermatitis from a United States perspective15
Cost-effectiveness of mechanical thrombectomy versus intravenous thrombolysis in acute ischemic stroke: a systematic review14
The role of insurance policies in the drug pricing landscape13
Direct diabetes-related healthcare expenditures in Slovenia: recent evolution and future projections based on population-level data13
The impact of under-investment on health in Southern and Central Eastern European Countries12
A methodological guide for implementing and interpreting results of probabilistic analysis12
Time from approval to reimbursement recommendations in healthcare systems with centralized HTA processes. Focus on the Polish HTA agency12
Cost effectiveness of non-pharmacological interventions for fatigue in patients with long-term conditions: a systematic literature review12
A projected cost-utility analysis of avacopan for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis in Spain12
Consumption of antidepressants and economic austerity in Brazil12
Cost-effectiveness analysis of tofacitinib for the treatment of moderate to severe rheumatoid arthritis: a systematic review and meta-analysis11
Cost-effectiveness comparison of dalpiciclib and abemaciclib combined with an aromatase inhibitor as first-line treatment for HR+/HER2− advanced breast cancer11
International comparability of reference unit costs of education services: when harmonizing methodology is not enough (PECUNIA project)10
Medication adherence research: expert perspectives on key HEOR trends for 202610
Mapping of the health of the Nation Outcomes Scale (HoNOS) and Positive and Negative Symptom Scale (PANSS) to the EQ-5D-3L in psychosis patients using the PHAMOUS study10
Cost-effectiveness analysis of nivolumab-chemotherapy as first-line therapy for locally advanced/metastatic gastric cancer: a United States payer perspective10
The impact of bone turnover marker on medication adherence and the health economics-related consequences10
Regulatory perspectives on post-market evidence generation schemes for high-risk medical devices: a systematic review9
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States9
Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric/gastroesophageal junction cancer in the Chinese healthcare system9
Cost consequence minimization and budget impact model for introducing the fully liquid combined acellular hexavalent vaccine into the Dominican Republic’s expanded immunization plan9
Systematic reviews of machine learning in healthcare: a literature review9
Access to medicines, care, and services for multiple sclerosis patients in Central and Eastern European countries: a comparative analysis9
Valuing quality of life for economic evaluations in cancer: navigating multiple methods9
Cost-utility analysis of multiple sclerosis rehabilitation in Iran9
Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis9
Digital measures in epilepsy in low-resourced environments9
Health and economic impact of 20-valent pneumococcal conjugate vaccine for adults aged 66–84 years in Japan and Shiga prefecture9
Cost–utility analysis of dupilumab compared with endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyps. Evaluation in Colombia, a developing country8
Individual vs societal perspectives: implications on quantitative benefit-risk assessment of vaccination8
Value elements and methods of value-based pricing for drugs in Japan: a systematic review8
Evaluation instruments for executive functions in children and adolescents: an update of a systematic review8
Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis8
Cost of rimegepant and lasmiditan associated adverse events, for acute treatment in migraine in Spain8
Adherence to oral anticoagulants in patients with non-valvular atrial fibrillation: the role of patients’ characteristics and out-of-pocket payments8
Impact of patient’s financial burden of COVID-19 treatment on antiviral prescription rates and clinical and economic outcomes8
Burden of illness among intermittent catheter users with non-neurogenic urinary retention in Denmark8
The pharmaceutical market: a transdisciplinary description of concepts and their implications7
Cost-utility analysis of osimertinib and dacomitinib in the first-line treatment of advanced non-small cell lung cancer with EGFR mutation7
Patients’ health related quality of life after massive weight loss reconstruction in the Netherlands7
Burden of disease of chronic pain in Ecuador7
Economic evaluation of an add-on module to reduce intrusive suicidal mental images in patients with depressive symptoms7
How relevant is the BMI for cost-of-illness studies in the 21st century?7
Physician and patient adherence in hypertension trials: a point of view on an important issue to resolve7
Knowledge, perception and application of pharmacoeconomics among healthcare professionals in Malaysia7
The socioeconomic burden of cervical cancer and its implications for strategies required to achieve the WHO elimination targets7
Systematic review on the use of cost-benefit analysis to evaluate food environment interventions7
Developing the Lebanese health economic evaluation guideline7
Real-world analysis of the economic and therapeutic burden in advanced breast cancer patients in Italy7
A retrospective observational analysis of the real-world care pathway of people with hereditary transthyretin amyloidosis with polyneuropathy in Italy6
Timely access to new drugs in a single-payer system: policy analysis from South Korea’s reimbursement framework6
Intravenous and subcutaneous vedolizumab for moderately to severely active ulcerative colitis in Iran: a model-based cost-effectiveness evaluation6
Qualitative research on the acceptance of evolving evidence for HTA body approval of innovative health technologies in selected European countries6
The potential public health impact of new immunization strategies for the prevention of RSV in children in Panama6
Mapping the World Health Organization Disability Assessment Scale 2.0 to the EQ-5D-5L in patients with mental disorders6
The hidden burden of atopic dermatitis in central and Eastern European countries6
Bridging the gap: enhancing medication adherence through research and innovation6
Management of low back pain in the Brazilian public health system: budget impact analysis of the implementation of Pilates exercises compared to usual care6
Valuing prevention: lessons and recommendations from a Dutch expert committee6
Economic analysis of cerliponase alfa for treatment of late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2)6
Incorporating diagnostic testing into economic evaluations of tumour-agnostic therapies6
Precision medicine in Thoracic Oncology: understanding disparities to tackle inequities in access6
Economic and humanistic burden of chronic liver diseases in the United States6
Transdisciplinary health economics for 2050: the challenge of preventing the adverse health effects of obesity, inequalities, and climate change6
Are quality-adjusted life years (QALYs) becoming more expensive? Evidence from economic evaluations of diabetic therapeutics6
Reimagining pharmacoeconomics in the age of artificial intelligence: opportunities, challenges, and future directions6
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma6
Development and implementation of a stratified enhanced recovery after surgery pathway for ventral hernia repair6
A comprehensive measurement of hemophilia economic burden in Iraq: a field-based study5
Economic benefits of global Collaborative Health technology5
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation5
Preferences of people with diabetes for diabetes care in Germany: a discrete choice experiment5
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran5
Clinical and economic outcomes associated with intravenous albumin fluid use in the intensive care unit: a retrospective cohort study5
Healthcare costs, resource utilization, and productivity loss associated with colorectal cancer screening5
Adherence to asthma and COPD inhaled therapies in low- and middle-income countries: a narrative review5
How do patients value features of biological medicine in rheumatoid arthritis? A discrete choice experiment5
Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines – a case study of oncology drugs5
Budget impact analysis of transurethral water vapor therapy for treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in the Spanish national healthcare system5
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data5
Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review5
A cost analysis of a simplified model for HCV screening and treatment at a tertiary hospital in Zimbabwe5
Workplace productivity losses due to cancer: findings from an Australian longitudinal population survey (2009–2021)5
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain5
Digital decision aids and prenatal outcomes: a systematic review and meta-analysis5
Economic burden of cervical cancer and premalignant lesions associated with human papilloma virus: a societal perspective4
A roadmap for applying machine learning when working with privacy-sensitive data: predicting non-response to treatment for eating disorders4
Value assessment of new interventions for Alzheimer’s disease dementia in Japan based on literature review and group interview4
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in Greece4
Use of machine learning to predict bladder cancer survival outcomes: a systematic literature review4
Psychometric properties of outcome measures for freezing of gait in Parkinson’s disease: a systematic review and meta-analysis4
The value of functional genomics: a contingent valuation4
The Lebanese health economic evaluation guideline4
The impact of comprehensive public hospital reform on economic burden of inpatients with chronic obstructive pulmonary disease: evidence from a pilot city in western China4
Cost-utility of sintilimab plus chemotherapy vs chemotherapy as first-line treatment of advanced gastric or gastroesophageal junction cancer in China4
Perspectives in prospective comparative economic evaluations: a systematic review4
Improved medication adherence in COPD patients using tiotropium or tiotropium olodaterol with the HealthPrize digital behavior change program4
Design and testing of a health economic Markov model for treatment of anorexia nervosa4
Correction4
Negating the burden of hip fracture in high-risk populations: a narrative review of epidemiology, costs, and multifaceted mitigation strategies4
Costs for global guideline-based diagnosis of mucormycosis in patients with neutropenia, hematopoietic stem cell, or solid organ transplantation – a perspective of the German healthcare system4
Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 – 20204
The economics of prevention and quality of care: policy insights from the EU’s COVID-19 response4
Cost-effectiveness of HIV prevention interventions in sub-Saharan Africa (2019–2025): a systematic review4
Enhancing pharmacist intervention targeting based on patient clustering with unsupervised machine learning4
Trastuzumab deruxtecan versus chemotherapy treated in patients with HER2-positive metastatic breast cancer: a cost-effectiveness analysis based on the DESTINY-Breast02 trial4
Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model4
The short-term impact of copayment reductions for government subsidised medicines in Australia4
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective4
Perceptions of risk sharing agreements in South Korea from the viewpoints of key stakeholders: a convergent parallel mixed approach4
The economic impact of pharmacist intervention during pandemics4
Cost-effectiveness of toripalimab plus chemotherapy versus chemotherapy as first-line treatment for advanced non-small cell lung cancer in China: a societal perspective4
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions4
Cost-effectiveness analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands4
Implementing a Managed Entry Agreement Framework in Cyprus4
Evaluating reporting of patient-reported outcomes in peptic ulcer disease: a meta-epidemiological study of randomized controlled trials4
0.96725797653198